Indian AI Chip Startup Ceremorphic Enters Drug Development

Translated data: India's Ceremorphic company has launched a life sciences division, utilizing its AI chip technology platform BioCompDiscoverX to accelerate drug development. The company aims to identify better candidate molecules from the outset, bringing new drugs to market faster and more cost-effectively. Ceremorphic plans to fully roll out its technology platform by the end of 2024.

Artificial Intelligence Chip Manufacturer Cerebras Successfully Lists on the Stock Market, Valuation Surges to $60 Billion

Cerebras Systems successfully went public in 2026, raising $5.5 billion through its IPO, and its valuation surged to approximately $60 billion, making its founder a billionaire. The company was founded in 2016 and focuses on AI chip manufacturing, but it nearly went bankrupt in 2019, with monthly expenses of $8 million, almost exhausting its funds.

Arm expects AI chip sales to reach $2 billion next year

British semiconductor company Arm announced that its first self-developed AI chip is expected to generate $2 billion in sales next year, as market demand is strong. This move marks a significant breakthrough for Arm in the AI field. As a subsidiary of SoftBank, Arm holds a key position in the global semiconductor market, with its technology widely used in electronic devices. The launch of the new chip comes at a time when AI technology is rapidly developing and the demand for high-performance computing is increasing.

OpenAI Launches GPT-Rosalind Model, Deeply Crossing into the Field of Pharmaceutical and Life Sciences

OpenAI launches GPT-Rosalind, an AI model for life sciences named after DNA pioneer, designed to accelerate drug discovery by analyzing biochemical data to aid in evidence synthesis, hypothesis generation, experimental planning, and protein engineering, enhancing lab efficiency and medical application.....

New Breakthrough in the Field of Chemical AI! Tsinghua AIR Collaborates with Shuimu Molecules to Open Source the General-Purpose Large Model BioMedGPT-Mol

The Tsinghua Institute for Intelligent Technology Research collaborates with Shuimu Molecules to open source the general-purpose chemical molecule model BioMedGPT-Mol, marking a significant step in the deepening of domestic large models from general dialogue to specialized fields such as biomedicine. This model is specifically designed for chemical molecules, aiming to promote the intelligence and standardization of drug development.

27 Billion Dollar Bet: Meta and Nebius Sign a Five-Year AI Computing Capacity Expansion Agreement

Meta has signed an infrastructure agreement worth up to 27 billion dollars with cloud service provider Nebius, ensuring sufficient advanced computing power for the next five years to cope with global AI competition. The agreement includes 12 billion dollars in dedicated computing capacity and 15 billion dollars in optional expansion, highlighting Meta's urgent need for computing power reserves.